NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) announced its earnings results on Tuesday, October, 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. The medical research company earned $104.70 million during the quarter, compared to analyst estimates of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The firm's quarterly revenue was up 51.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.05 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for NeoGenomics.

NeoGenomics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

7 Wall Street analysts have issued 1 year price targets for NeoGenomics' stock. Their forecasts range from $14.00 to $35.00. On average, they expect NeoGenomics' stock price to reach $24.67 in the next year. This suggests that the stock has a possible downside of 24.1%. View Analyst Price Targets for NeoGenomics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

Headlines about NEO stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeoGenomics earned a news impact score of -1.9 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for NeoGenomics.

NeoGenomics saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 6,310,000 shares, a decline of 8.8% from the January 15th total of 6,920,000 shares. Based on an average trading volume of 745,100 shares, the days-to-cover ratio is currently 8.5 days. Approximately 6.4% of the shares of the company are short sold. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Cochlear (COH), Insulet (PODD), EXACT Sciences (EXAS), Varian Medical Systems (VAR), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), BioMerieux (BMXMF), Bausch Health Companies (BHC), Universal Health Services (UHS), Bio-Rad Laboratories (BIO), BioScrip (BIOS), Bio-Rad Laboratories (BIO.B), Elanco Animal Health (ELAN), Davita (DVA) and Mylan (MYL).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), Marvell Technology Group (MRVL), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Canopy Growth (CGC), Amarin (AMRN), Netflix (NFLX) and CVS Health (CVS).

NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Kopp Family Office LLC (4.64%), Janus Henderson Group PLC (3.33%), Artisan Partners Limited Partnership (2.81%), State Street Corp (2.65%), Eagle Asset Management Inc. (2.38%) and Granite Investment Partners LLC (1.84%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Marshall Wace LLP, Emerald Advisers LLC, Franklin Resources Inc., Eagle Asset Management Inc., Janus Henderson Group PLC, Falcon Point Capital LLC and Nicholas Investment Partners LP. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was acquired by a variety of institutional investors in the last quarter, including Kopp Family Office LLC, Artisan Partners Limited Partnership, Redwood Investments LLC, Driehaus Capital Management LLC, Candriam Luxembourg S.C.A., TCW Group Inc., California Public Employees Retirement System and Bullseye Asset Management LLC. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $32.49.

NeoGenomics has a market capitalization of $3.39 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]